Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E83.24 EPS (ttm)0.69 Insider Own0.20% Shs Outstand142.52M Perf Week-5.04%
Market Cap8.14B Forward P/E407.86 EPS next Y0.14 Insider Trans-13.43% Shs Float133.64M Perf Month-5.46%
Income97.70M PEG1.70 EPS next Q0.93 Inst Own86.90% Short Float7.26% Perf Quarter-4.34%
Sales821.00M P/S9.91 EPS this Y-151.00% Inst Trans-1.36% Short Ratio10.75 Perf Half Y-15.84%
Book/sh9.51 P/B6.00 EPS next Y-91.61% ROA15.20% Target Price71.06 Perf Year-2.83%
Cash/sh15.58 P/C3.66 EPS next 5Y49.00% ROE35.40% 52W Range53.34 - 86.58 Perf YTD-5.48%
Dividend- P/FCF51.25 EPS past 5Y4.50% ROI-6.00% 52W High-35.83% Beta2.06
Dividend %- Quick Ratio10.30 Sales past 5Y32.40% Gross Margin99.40% 52W Low4.16% ATR1.71
Employees737 Current Ratio10.40 Sales Q/Q15.50% Oper. Margin14.10% RSI (14)30.71 Volatility2.76% 2.49%
OptionableYes Debt/Eq0.00 EPS Q/Q673.50% Profit Margin52.30% Rel Volume0.82 Prev Close57.10
ShortableYes LT Debt/Eq0.49 EarningsFeb 26 BMO Payout0.00% Avg Volume902.50K Price55.56
Recom2.70 SMA20-7.32% SMA50-8.90% SMA200-11.25% Volume563,129 Change-2.70%
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Feb-24-20 05:44AM  How biotech Alnylam plans to make a profit, and what stands in its way American City Business Journals -5.60%
Feb-20-20 03:59AM  UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven CMBS classes of UBSCM 2017-C3 Moody's
Feb-19-20 09:01PM  UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven CMBS classes of UBSCM 2017-C3 Moody's
12:31PM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
07:05AM  Ionis Pharmaceuticals to hold 2019 financial results webcast PR Newswire
Feb-13-20 07:00AM  Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman GlobeNewswire
Feb-11-20 11:40AM  GRFS vs. IONS: Which Stock Is the Better Value Option? Zacks
07:05AM  Ionis treatment for Alexander disease granted orphan drug status from EMA PR Newswire
Feb-07-20 10:00AM  Ionis Pharmaceuticals (NASDAQ:IONS) Has A Rock Solid Balance Sheet Simply Wall St.
Feb-06-20 04:08PM  This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run Investor's Business Daily
Jan-30-20 02:57PM  6 Stocks Killing Gurus' Returns GuruFocus.com
Jan-28-20 04:05PM  Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx GlobeNewswire
Jan-22-20 04:29PM  Will These Biotechs Rival A Top-Notch Stock In High Triglycerides? Investor's Business Daily
07:05AM  Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx PR Newswire
Jan-16-20 05:00AM  Top Picks 2020- Ionis Pharmaceuticals IONS MoneyShow
Jan-13-20 01:02PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Jan-12-20 03:39PM  How Did Ionis Pharmaceuticals, Inc. (IONS) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-10-20 07:00AM  Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy GlobeNewswire
Jan-09-20 07:05AM  Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer PR Newswire
07:00AM  Johnson & Johnson spinout signs licensing, collaboration deal worth up to $1.4B American City Business Journals
Jan-07-20 12:14PM  /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ PR Newswire
Jan-06-20 07:05AM  Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference PR Newswire
Jan-02-20 08:00AM  New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease GlobeNewswire
Dec-31-19 06:10AM  Experts question Cambridge biotech's strategy after trial failure American City Business Journals
Dec-24-19 09:27AM  Why Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Looks Like A Quality Company Simply Wall St.
07:00AM  Heres to Your Health: A Decade of Drug Breakthroughs Bloomberg
Dec-19-19 07:05AM  Ionis licenses investigational Alzheimer's therapy PR Newswire
Dec-18-19 10:03PM  Akcea Retains Rights to AKCEA-APOCIII-LRx GlobeNewswire
07:05AM  Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research PR Newswire
Dec-16-19 11:34PM  Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial PR Newswire
Dec-12-19 03:19PM  ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study Zacks
07:05AM  Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024 PR Newswire
Dec-06-19 11:33AM  Hedge Funds Have Never Been This Bullish On Ionis Pharmaceuticals, Inc. (IONS) Insider Monkey
Dec-04-19 07:00AM  Akcea Announces Appointment of New Chief Operating Officer GlobeNewswire
Dec-02-19 07:05AM  Ionis Pharmaceuticals to hold technology webcast PR Newswire
Nov-25-19 07:00AM  Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis GlobeNewswire
Nov-20-19 10:20AM  Surging Earnings Estimates Signal Upside for Ionis Pharmaceuticals (IONS) Stock Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
Nov-19-19 04:05PM  Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Nov-18-19 12:00PM  Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference PR Newswire
11:11AM  Estimating The Fair Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Simply Wall St.
Nov-13-19 01:25AM  Edited Transcript of IONS earnings conference call or presentation 6-Nov-19 4:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:05AM  Ionis Pharmaceuticals to present at upcoming investor conferences PR Newswire
Nov-06-19 04:14PM  Here's One Drugmaker That Popped On Earnings And Two That Didn't Investor's Business Daily
08:35AM  Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM  Ionis provides third quarter financial results and improved 2019 guidance PR Newswire
Oct-30-19 10:34AM  Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 07:05AM  Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference PR Newswire
Oct-25-19 08:37AM  Ionis Pharmaceuticals Enters Oversold Territory Zacks
Oct-23-19 07:05AM  Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences PR Newswire
Oct-22-19 07:05AM  Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast PR Newswire
07:00AM  Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast GlobeNewswire
Oct-20-19 03:03PM  Is Ionis Pharmaceuticals, Inc. (IONS) A Good Stock To Buy? Insider Monkey
Oct-10-19 08:00AM  Ionis Jumps After Vote of Confidence in Drug Pipeline TheStreet.com
07:05AM  Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting PR Newswire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
06:50AM  Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results PR Newswire
Oct-07-19 04:13PM  How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume Investor's Business Daily
10:57AM  Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers? Simply Wall St.
06:50AM  Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Oct-01-19 06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals
Sep-26-19 11:32AM  Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN Zacks
Sep-25-19 10:05AM  Ionis to receive the CLSA's 2019 Pantheon DiNA Award for Company of the Year PR Newswire
Sep-23-19 09:43AM  Akcea's stock drops after 3 top executives leave company, including CEO MarketWatch
09:40AM  Akcea Therapeutics shakes up executive suite, board in 'disconcerting' move American City Business Journals
Sep-19-19 11:30AM  Biogen's New Study to Test Higher Dose of SMA Drug Spinraza Zacks
Sep-18-19 07:30AM  Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients GlobeNewswire
Sep-17-19 10:23PM  Positive preliminary results from ATL1102 for DMD Phase II trial PR Newswire
Sep-16-19 07:00AM  Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting GlobeNewswire
Sep-05-19 09:17AM  If You Had Bought Ionis Pharmaceuticals (NASDAQ:IONS) Shares Three Years Ago You'd Have Made 107% Simply Wall St.
Sep-03-19 08:01AM  How Biotech Companies Are Targeting RNA to Cure Diseases Barrons.com
Aug-29-19 07:00AM  Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings GlobeNewswire
Aug-28-19 02:15PM  Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks
07:05AM  Ionis Pharmaceuticals to present at upcoming investor conferences PR Newswire
Aug-27-19 07:05AM  Ionis licenses hepatitis B program to GSK PR Newswire
Aug-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman and CEO Stanley T Crooke Sold $1.6 million of Shares GuruFocus.com -5.96%
Aug-15-19 03:50PM  Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-14-19 01:47PM  Ionis Pharmaceuticals Looks to Partners to Pay the Bills Motley Fool
09:15AM  Market Takes Off After Tariffs Pushed Back Zacks
09:13AM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT Thomson Reuters StreetEvents
08:53AM  3 Charts That Suggest Now Is the Time to Buy Into Biotech Investopedia
Aug-07-19 05:10PM  New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome GlobeNewswire +5.63%
08:15AM  Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34AM  The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout Benzinga
07:00AM  Ionis Reports Second Quarter 2019 Financial Results PR Newswire
Aug-06-19 04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2019 GlobeNewswire
04:05PM  Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy GlobeNewswire
08:54AM  Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet? Simply Wall St.
Jul-31-19 10:36AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
09:15AM  Rate Cut Wait Almost Over Zacks
Jul-30-19 10:38AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
07:05AM  Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast PR Newswire
Jul-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman & CEO Stanley T Crooke Sold $702,500 of Shares GuruFocus.com
Jul-19-19 06:00AM  Ionis Pharmaceuticals IONS- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:15AM  Late Surge Helps S&P Join NASDAQ in the Green Zacks
Jul-01-19 07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients PR Newswire
07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients GlobeNewswire
Jun-30-19 12:15PM  3 Top Biotech Stocks to Add to Your Watchlist Motley Fool
Jun-29-19 04:00AM  Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy GlobeNewswire
Jun-21-19 12:13PM  Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) A High Quality Stock To Own? Simply Wall St.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'NEIL PATRICK R.SVP & General CounselFeb 10Sale59.603,882231,36720,720Feb 11 05:40 PM
Swayze EricSVP, ResearchJan 15Option Exercise0.006,52207,290Jan 17 06:47 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0015,136068,702Jan 17 06:42 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 15Option Exercise0.0012,045028,879Jan 17 06:39 PM
Monia Brett PChief Executive OfficerJan 15Option Exercise0.0019,921036,206Jan 17 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 15Option Exercise0.0012,044036,504Jan 17 06:33 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.0013,139034,722Jan 17 06:30 PM
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.003,31708,849Jan 17 06:28 PM
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.0039,6430109,277Jan 17 06:28 PM
BENNETT C FRANKChief Scientific OfficerJan 15Option Exercise0.0011,711036,357Jan 17 06:11 PM
Monia Brett PChief Executive OfficerJan 02Sale60.2517310,42316,285Jan 03 07:04 PM
KLEIN JOSEPH IIIDirectorDec 23Option Exercise35.531,00035,53013,683Dec 23 07:28 PM
KLEIN JOSEPH IIIDirectorDec 23Sale61.871,00061,87412,683Dec 23 07:28 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 20Option Exercise10.8210,634115,06027,251Dec 20 07:23 PM
KLEIN JOSEPH IIIDirectorDec 16Option Exercise35.531,00035,53013,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 16Sale65.451,00065,44712,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 09Option Exercise35.531,00035,53013,683Dec 10 06:54 PM
KLEIN JOSEPH IIIDirectorDec 09Sale63.741,00063,74512,683Dec 10 06:54 PM
Geary Richard SSVP, DevelopmentDec 04Option Exercise14.6910,000146,90031,583Dec 05 05:26 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Option Exercise10.824,56649,40424,117Dec 05 05:31 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Sale65.004,566296,79020,055Dec 05 05:31 PM
Geary Richard SSVP, DevelopmentDec 04Sale65.0010,000650,00021,583Dec 05 05:26 PM
Geary Richard SSVP, DevelopmentDec 02Option Exercise14.695,00073,45026,583Dec 04 06:22 PM
KLEIN JOSEPH IIIDirectorDec 02Option Exercise35.531,00035,53013,683Dec 04 06:26 PM
KLEIN JOSEPH IIIDirectorDec 02Sale64.081,00064,08312,683Dec 04 06:26 PM
Geary Richard SSVP, DevelopmentDec 02Sale65.065,000325,28721,583Dec 04 06:22 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Option Exercise10.824,00043,28024,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 25Sale62.9081251,07512,683Nov 26 05:43 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Sale62.504,000250,00020,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 20Sale60.002,000120,00013,495Nov 21 06:40 PM
Monia Brett PCOO & SVP, Translational MedNov 20Sale60.015,776346,61816,458Nov 21 06:38 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Option Exercise10.824,00043,28024,055Nov 21 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Sale58.804,000235,20020,055Nov 21 06:36 PM
Hayden Michael RDirectorOct 15Option Exercise0.001,77801,778Oct 17 05:52 PM
Reikes Peter NDirectorOct 15Option Exercise0.001,77801,778Oct 17 05:15 PM
CROOKE STANLEY TChairman and CEOAug 21Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 21Sale72.1510,000721,50069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.872,00079,7407,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.002,000142,0005,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.0010,000710,00069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman & CEOJul 18Option Exercise39.8710,000398,70079,634Jul 22 05:34 PM
CROOKE STANLEY TChairman & CEOJul 18Sale70.2510,000702,50669,634Jul 22 05:34 PM
McDevitt DamienChief Business OfficerJul 15Option Exercise0.003,54203,798Jul 17 05:39 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667015,495Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 03Option Exercise0.00667012,683Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667013,308Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667061,805Jul 03 06:34 PM
PARSHALL B LYNNEDirectorJul 02Option Exercise0.00889053,566Jul 03 06:49 PM
KLEIN JOSEPH IIIDirectorJul 02Option Exercise0.00889014,828Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 02Option Exercise0.00889012,016Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 02Option Exercise0.00889012,641Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 02Option Exercise0.00889061,138Jul 03 06:34 PM
Monia Brett PChief Operating OfficerJul 02Sale66.4021013,94422,234Jul 02 08:50 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.001,333013,939Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 01Option Exercise0.001,333011,127Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.001,333011,752Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.001,333060,249Jul 03 06:34 PM
BERTHELSEN SPENCER RDirectorJun 24Option Exercise16.3215,000244,800103,784Jun 26 06:52 PM
BERTHELSEN SPENCER RDirectorJun 24Sale63.6715,000955,11394,094Jun 26 06:52 PM
MUTO FREDERICK TDirectorJun 04Option Exercise16.3215,000244,80024,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorJun 04Sale65.2915,000979,3509,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorMay 06Option Exercise24.428,000195,36017,794May 08 06:16 PM
MUTO FREDERICK TDirectorMay 06Sale72.758,000582,0029,794May 08 06:16 PM
PARSHALL B LYNNEDirectorApr 29Option Exercise39.8750,0001,993,500102,677May 01 05:48 PM
PARSHALL B LYNNEDirectorApr 29Sale75.0150,0003,750,63552,677May 01 05:48 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.161,00031,1556,232Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.4620,000629,19882,954Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.751,00084,7505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.6220,0001,692,50069,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise10.821,00010,8206,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise14.6910,000146,90079,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.251,00085,2505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.2510,000852,50069,634Apr 17 07:30 PM
Geary Richard SSVP, DevelopmentApr 08Option Exercise42.5346,2401,966,46645,442Apr 10 06:24 PM
Geary Richard SSVP, DevelopmentApr 08Sale84.0146,2403,884,75321,442Apr 10 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Option Exercise61.682,252138,90318,925Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Sale84.752,252190,85716,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Option Exercise56.7636,6222,078,80935,165Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Sale83.7939,6223,319,92916,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Option Exercise61.687,654472,09927,327Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Sale84.837,654649,28919,673Apr 05 07:29 PM
WENDER JOSEPH HDirectorMar 19Sale79.6310,000796,25858,916Mar 20 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Option Exercise61.5728,8001,773,21648,473Mar 20 06:15 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Sale78.7928,8002,269,18719,673Mar 20 06:15 PM
PARSHALL B LYNNEDirectorMar 12Option Exercise39.878,334332,27761,011Mar 14 06:24 PM
PARSHALL B LYNNEDirectorMar 12Sale75.008,334625,05052,677Mar 14 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Option Exercise45.1126,8001,208,95233,773Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Option Exercise39.878,333332,23761,010Mar 01 05:56 PM
PARSHALL B LYNNEDirectorFeb 27Sale70.008,333583,31052,677Mar 01 05:56 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Sale68.0126,8001,822,58019,673Mar 01 05:40 PM
CROOKE STANLEY TChairman and CEOFeb 26Option Exercise39.8737,0001,475,190106,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 26Sale61.5437,0002,276,79969,634Feb 27 07:31 PM
open in yahoo | open in reuters | open in google